The FDA has approved axicabtagene ciloleucel (Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. It is the second CAR T-cell immunotherapy to become available in the US. Tisagenlecleucel (Kymriah), a CAR T-cell product previously approved for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients ≤25 years old,1 was recently also approved for relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy.

TREATMENT OF LARGE B-CELL LYMPHOMA — Most cases of diffuse large B-cell lymphoma, the most ... more      

Would you like to read the rest of this article?  Gain access below.